{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-025201","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.721789+00:00","generated_at":"2026-05-15T17:52:41.282220+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Voyager Q4 2025 net loss $27.4M, cash $201.7M; key pipeline milestones H2 2026","bullets":["Q4 2025 net loss $27.4M vs $34.5M in Q4 2024; full year net loss $119.7M vs $65.0M.","Collaboration revenue Q4 $15.3M (up 143% YoY) but full year $40.4M (down 50% YoY).","Cash $201.7M at Dec 31 2025; runway expected into 2028 with up to $2.4B in milestone potential.","VY1706 (tau-silencing) IND planned Q2 2026, first-in-human dosing H2 2026; VY7523 tau PET data H2 2026.","APOE gene therapy program paused; Neurocrine milestone $3M triggered in Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-025201","json":"https://secwatch.observer/filing/0001104659-26-025201.json","markdown":"https://secwatch.observer/filing/0001104659-26-025201.md","text":"https://secwatch.observer/filing/0001104659-26-025201.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000110465926025201/0001104659-26-025201-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000110465926025201/vygr-20260309x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T17:52:41.282220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}